ArticlePhytotherapy research : PTR2026
Epigallocatechin-3-Gallate Suppresses Glioma by Targeting Integrin αvβ3/FAK/ERK Signaling Axis and Matrix Metalloproteinases.
Article in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Epigallocatechin-3-gallate (EGCG), the most abundant and biologically active catechin in green tea, has been widely reported to exhibit anti-cancer properties in various tumor types. However, its therapeutic potential and underlying mechanisms on glioma remain ambiguous. This study aimed to investigate the in vitro and in vivo effects of EGCG on glioma, with a specific focus on elucidating its molecular mechanisms, particularly the modulation of integrin-mediated signaling pathways and matrix metalloproteinases' (MMPs) expressions. The anti-proliferative effects of EGCG were evaluated in human glioma cell lines (U87, U251, and LN229) using CCK-8, EdU, and colony formation assays. Cell migration and invasion were assessed by wound healing and transwell assays, while apoptosis was analyzed via flow cytometry. The potential molecular mechanisms underlying the inhibitory effects of EGCG on integrin αvβ3/FAK/ERK signaling pathway and MMP-2/MMP-9 were explored by western blotting analyses. In vivo antitumor efficacy of EGCG was evaluated using an intracranial xenograft model in nude mice, with or without co-administration of temozolomide (TMZ). Toxicity was monitored through body weight changes and histopathological examination. EGCG inhibited cell proliferation with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.